RECURSION PHARMACEUTICALS, INC. Other Noncash Income (Expense)
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Other Noncash Income (Expense) of -$2.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$740.00K.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$1.67M.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$2.90M.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was $2.22M.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2025 was -$9.55M.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2024 was -$16.34M, a 725.30% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2023 was $2.61M.
- RECURSION PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2022 was -$830.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$740.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.41M 10-Q · filed 2026-08-05 | -$5.31M derived: sum of 3 quarters · filed 2026-08-05 | -$3.08M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$1.67M 10-Q · filed 2026-05-06 | -$4.57M derived: sum of 2 quarters · filed 2026-05-06 | -$2.35M derived: sum of 3 quarters · filed 2026-05-06 | -$6.40M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$671.00K derived: sum of 2 quarters · filed 2026-02-25 | -$4.73M derived: sum of 3 quarters · filed 2026-08-05 | -$9.55M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.83M derived: sum of 2 quarters · filed 2026-08-05 | -$6.66M 10-Q · filed 2025-11-05 | -$23.64M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$8.88M 10-Q · filed 2026-08-05 | -$9.10M 10-Q · filed 2025-08-05 | -$25.87M derived: sum of 3 quarters · filed 2026-08-05 | -$31.72M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$4.82M 10-Q · filed 2026-05-06 | -$4.41M 10-Q · filed 2025-05-05 | -$21.81M derived: sum of 2 quarters · filed 2026-05-06 | -$27.66M derived: sum of 3 quarters · filed 2026-05-06 | -$21.72M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$16.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$22.84M derived: sum of 2 quarters · filed 2026-02-25 | -$16.90M derived: sum of 3 quarters · filed 2026-02-25 | -$16.34M 10-K · filed 2026-02-25 | -$7.58M 10-K · filed 2025-02-28 | ||
| 2024-09-30 | -$5.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $90.00K derived: sum of 2 quarters · filed 2025-11-05 | $650.00K 10-Q · filed 2025-11-05 | $2.15M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $5.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $6.50M 10-Q · filed 2025-08-05 | $3.57M 10-Q · filed 2024-08-08 | $8.00M derived: sum of 3 quarters · filed 2026-02-25 | $9.85M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $560.00K 10-Q · filed 2025-05-05 | $2.06M derived: sum of 2 quarters · filed 2026-02-25 | $3.91M derived: sum of 3 quarters · filed 2026-02-25 | $3.89M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.35M derived: sum of 2 quarters · filed 2026-02-25 | $3.33M derived: sum of 3 quarters · filed 2026-02-25 | $2.61M 10-K · filed 2026-02-25 | -$3.39M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.83M derived: sum of 2 quarters · filed 2024-11-06 | $1.11M 10-Q · filed 2024-11-06 | $661.00K derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$739.00K 10-Q · filed 2024-08-08 | -$1.19M derived: sum of 3 quarters · filed 2025-02-28 | -$975.00K derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-03-31 | -$716.00K 10-Q · filed 2024-05-09 | -$1.17M derived: sum of 2 quarters · filed 2025-02-28 | -$952.00K derived: sum of 3 quarters · filed 2025-02-28 | -$1.14M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | -$453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$236.00K derived: sum of 2 quarters · filed 2025-02-28 | -$428.00K derived: sum of 3 quarters · filed 2025-02-28 | -$830.00K 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $25.00K derived: sum of 2 quarters · filed 2023-11-09 | -$377.00K 10-Q · filed 2023-11-09 | -$1.53M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$594.00K 10-Q · filed 2023-08-08 | -$1.75M derived: sum of 3 quarters · filed 2024-02-29 | -$2.21M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | -$402.00K 10-Q · filed 2023-05-08 | -$1.56M derived: sum of 2 quarters · filed 2024-02-29 | -$2.02M derived: sum of 3 quarters · filed 2024-02-29 | -$4.40M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$1.62M derived: sum of 2 quarters · filed 2024-02-29 | -$4.00M derived: sum of 3 quarters · filed 2024-02-29 | -$4.10M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.84M derived: sum of 2 quarters · filed 2022-11-08 | -$2.94M 10-Q · filed 2022-11-08 | -$3.41M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.48M 10-Q · filed 2022-08-09 | -$2.95M derived: sum of 3 quarters · filed 2023-02-27 | -$3.40M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | -$101.00K 10-Q · filed 2022-05-10 | -$573.00K derived: sum of 2 quarters · filed 2023-02-27 | -$1.03M derived: sum of 3 quarters · filed 2023-02-27 | -$860.00K derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | -$472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$925.00K derived: sum of 2 quarters · filed 2023-02-27 | -$759.00K derived: sum of 3 quarters · filed 2023-02-27 | -$781.00K 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$453.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$287.00K derived: sum of 2 quarters · filed 2021-11-10 | -$309.00K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $144.00K 10-Q · filed 2021-08-13 | |||||
| 2020-03-31 | -$22.00K 10-Q · filed 2021-05-12 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |